BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1375 related articles for article (PubMed ID: 8784084)

  • 1. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW; Lente JR
    J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
    Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
    Gamstedt A; Wadman B; Karlsson A
    J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?
    Kabadi UM; Premachandra BN
    Endocr Pract; 2007 Oct; 13(6):615-9. PubMed ID: 17954417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.